⌕
Edgewise Therapeutics · EWTX · Nasdaq
Tenet 69 · Solid
Compare
$43.68−4.90%At closeTenet 69 · Solid
$43.68−2.25 (−4.90%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Edgewise Therapeutics (EWTX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is EWTX's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● PRNewsWireNov 9, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Edgewise Therapeutics to Participate in Upcoming Investor Conferences

BOULDER, Colo., Nov. 9, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today announced that management will participate in the followin…

EWTX −4.9% todayRead at source ↗
● PRNewsWireNov 5, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring

– Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability – – STRATUS-HCM includes two independent placebo-cont…

EWTX −4.9% todayRead at source ↗
● PRNewsWireNov 4, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Edgewise Therapeutics Reports Third Quarter 2026 Financial Results

–  Published the differentiated mechanism of action of EDG-7500 that targets the regulatory light chain – –  Phase 3 trial for EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) on track to init…

EWTX −4.9% todayRead at source ↗
● PRNewsWireNov 2, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo., Nov. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today announced that on October 3…

EWTX −4.9% todayRead at source ↗
● PRNewsWireOct 8, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400

– Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at least 50% – – EQUINOX-HFpEF trial design and EDG-15400 Phase 1 first-in-human data to be presented at HFSA 2026 – BOULDER, Colo., Oc…

EWTX −4.9% todayRead at source ↗
● PRNewsWireOct 1, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo., Oct. 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announc…

EWTX −4.9% todayRead at source ↗
● Seeking AlphaSep 22, 2026 · 18:29 ET
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript

Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript…

EWTX −4.9% todayRead at source ↗
● PRNewsWireSep 22, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500

- The MoA that targets the Regulatory Light Chain (RLC) has shown in preclinical models to improve cardiac relaxation while preserving systolic function and cardiac reserve - - Company to host webcast to discuss these fi…

EWTX −4.9% todayRead at source ↗
● Schaeffers ResearchSep 18, 2026 · 11:46 ET
Biotech Options Buzz: UTHR, NMRA, EWTX

Biotech stocks are dominating today's unusual options volume list, with United Therapeutics Corporation (NASDAQ: UTHR), Neumora Therapeutics Inc (NASDAQ: NMRA), and Edgewise Therapeutics Inc (NASDAQ: EWTX) all attracting…

EWTX −4.9% todayRead at source ↗
● Defense WorldSep 11, 2026 · 03:39 ET
91,638 Shares in Edgewise Therapeutics, Inc. $EWTX Acquired by Hsbc Holdings PLC

Hsbc Holdings PLC purchased a new position in shares of Edgewise Therapeutics, Inc. (NASDAQ: EWTX) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. Th…

EWTX −4.9% todayRead at source ↗
● PRNewsWireSep 2, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo., Sept. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announ…

EWTX −4.9% todayRead at source ↗
● PRNewsWireAug 24, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026

– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) – BOULDER, Colo., Aug. 24, 2026 /PRNewswire/ -- Edg…

EWTX −4.9% todayRead at source ↗
● Seeking AlphaAug 18, 2026 · 10:52 ET
Edgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform

Edgewise Therapeutics (EWTX) has transformed into a well-capitalized cardiovascular drug developer following the $1.55B sale of sevasemten to Servier. EDG-7500, EWTX's lead asset, demonstrated robust Phase 2 efficacy in …

EWTX −4.9% todayRead at source ↗

No upcoming events in the feeds.

NVDA4−4.1%
BTC3−5.5%
STEM3−32.1%
ABR2−8.6%

Article counts from the last market-wide feed page, across every symbol we track and not just EWTX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.